Timolol eye drops 0.5%, gel forming (Timoptol XE): Discontinuation

Mundipharma has notified that it will discontinue the supply of timolol eye drops 0.5% (gel forming) (Pharmacode 204374).

Current supply of timolol eye drops 0.5% (gel forming) (Pharmacode 204374) is expected to be depleted by the end of September 2023.

This does not affect other presentations of timolol eye drops. 

Key dates:

1 April 2023: We are limiting access to people who were taking timolol eye drops 0.5% (gel forming) before this date.

September 2023: Existing stock of timolol eye drops 0.5% (gel forming) is expected to be exhausted.

1 March 2024: Timolol eye drops 0.5% (gel forming) will no longer be funded.

No new patients from 1 April 2023

We want to ensure supply of timolol eye drops 0.5% (gel forming) for existing patients for as long as possible. This will give people time to talk to their prescriber about alternative treatments. 

To achieve this, we have restricted dispensing to people who were using this treatment before 1 April 2023.

Pharmacists can endorse the script where they have a record of a previous dispensing of timolol eye drops 0.5% (gel forming). 

Alternatives to timolol eye drops 0.5% (gel forming) 

There are a number of fully funded treatment options available. Where appropriate, we encourage prescribers to discuss alternative options with their patients. 

Who to contact

If you take timolol eye drops 0.5% (gel forming), please talk to your pharmacist, doctor or the person who prescribed this medicine. They are best placed to discuss your individual clinical circumstances.

If you have a question about funding for dorzolamide eye drops or alternative treatments, email enquiry@pharmac.govt.nz